Internship

CMC Analytical Development Intern

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Healthcare

San Diego, CA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Pursuing a graduate degree with an interest in biotechnology
  • Specific degree or field required: Strong Liquid Chromatography-Mass Spectrometry Experience for Antibody and Antibody Conjugates
  • Prior experience in the pharmaceutical or biotechnology industry would be an asset but is not required
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes is desirable
  • Good verbal and written communication skills
  • Ability to think creatively and be a team player
  • Offer flexibility with a willingness to work on multiple projects simultaneously
  • Bring to the Company a skill set complementary to its technology and development therapeutics
  • Interest in attending various program events, including social gatherings, career development workshops, and more
  • Ability to commit to a 10-week, full-time summer program
  • Lab Work Requirements: Full-time
Responsibilities
  • Leading analytical method development for antibody conjugates with advanced analytical techniques such as mass spectrometry, liquid chromatography, capillary electrophoresis, etc.
  • Drafting method SOPs
  • Interacting with cross functional areas within the company including research & discovery, drug substance development and drug product development
  • Collaborating with a mentor team of cross-functional team members as well as the other interns in the class
  • Completing a special project and presenting the recommendations to senior management upon completion
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY offers a novel approach to treating classic congenital adrenal hyperplasia.
  • Neurocrine's workplace excellence enhances employee satisfaction and retention.
  • Patient-centric support programs improve outcomes for CRENESSITY users.

What critics are saying

  • Increased competition in the rare disease market may impact Neurocrine's market share.
  • Pricing pressures could affect the profitability of CRENESSITY.
  • Reliance on PANTHERx Rare for distribution poses a risk if disruptions occur.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's CRENESSITY is supported by the largest-ever clinical trial program for CAH.
  • Neurocrine partners with PANTHERx Rare for exclusive distribution of CRENESSITY.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays